StockWire X

StockWire X StockWire X is a mining-free digital publication delivering real-time investor news on ASX-listed tech, biotech, healthcare, industrials, and financials.

We help investors stay informed & give listed companies a smarter way to reach the right audience. Stock Wire X is Australiaโ€™s only investor news publication focused exclusively on non-mining ASX-listed companies. We deliver real-time, easy-to-understand updates on the companies shaping the future โ€” across technology, biotech, healthcare, industrials, and financials. In a market saturated with min

ing headlines, we give investors and listed companies a smarter alternative. Whether you're an investor looking for clarity or a company wanting to reach the right audience, Stock Wire X is built for you.

๐Ÿ‘‰ 100% non-resource coverage
๐Ÿ‘‰ Fast, factual, investor-focused news
๐Ÿ‘‰ No mining. No fluff. Just the other side of the ASX.

The ACCC has cleared the path for XPON's $5.5 million Datisan divestment โ€” and the 15 September General Meeting is now t...
09/09/2026

The ACCC has cleared the path for XPON's $5.5 million Datisan divestment โ€” and the 15 September General Meeting is now the next critical milestone.

The Australian Competition and Consumer Commission issued its Phase 1 determination allowing Incubeta Australia's proposed acquisition of Datisan to proceed, materially de-risking what the original agreement identified as the most significant completion risk among the three conditions precedent. A mandatory 14-day review period must expire without a third-party application before the clearance is formally satisfied, with full completion expected in late September 2026. The deal structure includes $5.5 million in cash at completion, plus a contingent earn-out of up to $2 million tied to Datisan's gross profit performance through 31 December 2026.

With the ACCC hurdle now progressed, shareholder approval at the 15 September General Meeting is the next decisive event on the path to settlement. Following completion, XPON intends to refocus entirely on its Wondaris AI Marketing Platform and pursue strategic acquisitions in the AI sector โ€” marking its second major portfolio restructure in 2026 after the earlier Alpha Digital divestment eliminated $2.4 million in debt obligations.

Get the full breakdown of the transaction terms, remaining conditions, and what completion means for XPON's AI pivot: https://stockwirex.com/asx-stock-news/tech-ai/xpn-xpon-technologies-datisan-divestment-accc-approval-september-2026/

Straker Limited has appointed a CFO who already knows the business inside out โ€” six years on the Board will do that.Aman...
09/09/2026

Straker Limited has appointed a CFO who already knows the business inside out โ€” six years on the Board will do that.

Amanda Cribb steps into the Chief Financial Officer role at Straker (ASX: STG) effective 9 September 2026, having served as a Non-Executive Director since 2020. She simultaneously resigned from the Board upon commencement, transitioning from boardroom oversight to hands-on executive leadership. Cribb brings a background spanning finance, technology, corporate strategy, and business transformation across senior roles in leading technology businesses.

Interim Co-CEO David Sowerby highlighted the strategic timing of the appointment: "Amanda's appointment strengthens our executive leadership as we focus on growing recurring revenues and accelerating commercialisation of Straker." The CFO appointment follows the broader leadership restructuring that began in March 2026, when Sowerby and Indy Nagpal stepped in as Co-CEOs following founder Grant Straker's transition to a Non-Executive Director role after 26 years at the helm.

Read the full executive profile and what this appointment means for Straker's growth agenda: https://stockwirex.com/asx-stock-news/communication-media/stg-straker-limited-cfo-appointment-september-2026/

Austal USA has attracted a US$1.25โ€“1.35 billion non-binding acquisition offer โ€” a potential transaction that would rank ...
09/09/2026

Austal USA has attracted a US$1.25โ€“1.35 billion non-binding acquisition offer โ€” a potential transaction that would rank among the largest defence-sector divestitures in the company's history.

A syndicate led by Wildcat Resources LLC has submitted a non-binding indication of interest to acquire Austal USA on a cash-free, debt-free basis. The proposal covers Austal's US shipbuilding operation, which delivers vessels and submarine modules across multiple active programmes including the Offshore Patrol Cutter, Littoral Combat Ship, Expeditionary Fast Transport, and nuclear submarine modules for Virginia and Columbia class submarines. The offer remains conditional on four weeks of due diligence, with no binding agreement in place and no transaction confirmed.

Wildcat Resources LLC has indicated its intention to operate Austal USA as a standalone platform, retaining the Austal brand and existing US operations. Importantly, the proposed transaction relates specifically to Austal USA โ€” Austal Limited's ASX listing, its Australian Strategic Shipbuilder appointment, and its shipyard operations in the Philippines and Vietnam are not part of the indication of interest. The Australian Strategic Shipbuilding Agreement, which now exceeds $5 billion in contracted value, provides the parent company with a long-duration revenue base independent of this process.

Read the full breakdown of the proposal terms, due diligence conditions, and what comes next for Austal Limited: https://stockwirex.com/asx-stock-news/industrials/asb-austal-usa-sale-wildcat-resources-september-2026/

The NIH has just awarded a multimillion-dollar, multiyear grant to fund an Expanded Access Protocol for NUZ-001 in ALS โ€”...
09/09/2026

The NIH has just awarded a multimillion-dollar, multiyear grant to fund an Expanded Access Protocol for NUZ-001 in ALS โ€” and Neurizon Therapeutics is receiving funding as subawardee, with the NIH covering all EAP-related drug supply, manufacturing, and specified regulatory costs.

The program is designed to provide up to 200 ALS patients who are ineligible for clinical trials with access to NUZ-001 for up to 96 weeks. Running in parallel with Regimen I of the Phase 2/3 HEALEY ALS Platform Trial โ€” which enrolled 250 participants across 78 US sites ahead of schedule โ€” the EAP will operate through approximately 20 physical sites plus a national virtual site, giving it potential reach across all 50 US states. Enrolment is targeted to commence in Q1 CY27, with Phase 2/3 topline results expected in late Q2 CY27.

Interim Executive Chairman Sergio Duchini noted: "The EAP will also significantly expand our long-term safety database and generate valuable biomarker, survival and real-world clinical data from a broader ALS population." The program is structured to complement โ€” not replace โ€” the controlled Phase 2/3 evidence base, capturing long-term safety, survival, and functional data from a patient population that randomised trials rarely reach. For investors, this means NUZ-001 is simultaneously building its clinical footprint across two distinct patient populations within a tightly aligned data readout window.

Read the full analysis of what the NIH grant means for NUZ-001's development pathway: https://stockwirex.com/asx-stock-news/biotech-health/nuz-neurizon-therapeutics-nih-expanded-access-als-september-2026/

The FDA has reviewed EBR Systems' cybersecurity risk assessment and confirmed no recall of the WiSEยฎ System is required ...
08/09/2026

The FDA has reviewed EBR Systems' cybersecurity risk assessment and confirmed no recall of the WiSEยฎ System is required โ€” a clean outcome that removes the most adverse scenario investors were watching for.

EBR first disclosed the cybersecurity incident to the ASX on 15 April 2026, having identified it internally in February 2026. The company moved quickly to contain the incident, engaged independent cybersecurity specialists, and submitted a formal risk assessment to the FDA. The regulator has now classified the incident as "Controlled Risk" under Section VI of its 2016 Postmarket Management of Cybersecurity in Medical Devices guidance โ€” the lower end of the risk spectrum โ€” and confirmed no field corrective action is warranted.

CEO John McCutcheon stated: "Patient safety, device integrity and responsible postmarket management remain EBR's highest priorities. Following submission of EBR's completed cybersecurity risk assessment, the FDA has advised that the incident aligns with a Controlled Risk classification and has agreed with EBR's response." With no safety or performance impact identified in fielded devices, the regulatory overhang that has been present since April is now formally resolved. EBR's commercial momentum continues in parallel, with 46 WiSE implants completed in Q2 2026, cumulative totals reaching 117 across 30 activated hospital accounts, and a potentially transformative CMS National Coverage Determination review underway with a projected Final NCD date of 3 March 2027.

Read the full analysis of what this FDA outcome means for EBR's investment case and regulatory outlook: https://stockwirex.com/asx-stock-news/biotech-health/ebr-fda-cybersecurity-clearance-september-2026/

Selective tumour uptake in every evaluable pancreatic cancer patient - that's the headline from Radiopharm Theranostics'...
08/09/2026

Selective tumour uptake in every evaluable pancreatic cancer patient - that's the headline from Radiopharm Theranostics' Phase 1 imaging trial of RAD301.

Radiopharm Theranostics (ASX: RAD) has released positive Phase 1 data for RAD301, its Gallium-68 peptide targeting ฮฑvฮฒ6-integrin in patients with Pancreatic Ductal Adenocarcinoma. The trial confirmed a favourable safety profile across all evaluable participants, favourable biodistribution across all dosed subjects, and significant, selective tumour uptake in pancreatic cancer metastases in every evaluable PDAC patient. Critically, low background uptake was observed in the liver, lung, and bowel - the primary sites of PDAC spread - supporting RAD301's ability to distinguish metastatic lesions from surrounding healthy tissue.

CEO Riccardo Canevari noted: "Given the limited imaging and treatment options available for patients with PDAC, these findings highlight the potential role of RAD301 in improving disease detection, patient selection, and future theranostic applications." The results support advancement into Phase 2 and extend beyond diagnostics - the same ฮฑvฮฒ6-integrin targeting mechanism could be adapted for therapeutic delivery, creating a dual diagnostic and treatment revenue stream from a single platform. RAD301 already holds FDA Orphan Drug Designation, adding regulatory momentum to the Phase 2 case.

Read the full clinical breakdown and what the Phase 2 pathway means for investors: https://stockwirex.com/asx-stock-news/biotech-health/rad-radiopharm-theranostics-rad301-phase-1-pancreatic-cancer-september-2026/

A US$172,500 fixed-price contract to design and build composite prototype airframes for an Israeli defence UAV โ€” KTEK Ae...
08/09/2026

A US$172,500 fixed-price contract to design and build composite prototype airframes for an Israeli defence UAV โ€” KTEK Aerosystems is putting its full-turnkey model to work.

KTEK Aerosystems (ASX: KTK) has entered a binding prototype development and manufacturing agreement with Israel-based Vestal Technology for the SCOOPER 25 unmanned aerial system. Under the contract, KTEK will advance the structural design to prototype-manufacturing maturity, manufacture tooling, complete static structural analysis, and produce two composite prototype airframes. The SCOOPER 25 has a maximum take-off mass of 25 kilograms and uses Vestal's patented SCOOP wing architecture, which is engineered for high lift at low speeds, extended endurance, and low acoustic and thermal signatures โ€” characteristics directly relevant to defence, surveillance, and special operations missions.

The first prototype airframe is targeted within five months of project commencement, with the second following approximately one month later, subject to configuration freeze and supplier availability. Founder and Managing Director Dekel Keisar noted: "This contract is a strong example of KTEK's full-turnkey model. We are bringing together our structural engineering, composite design, tooling and manufacturing capabilities to help take the SCOOPER 25 from preliminary design into physical prototypes." While the current agreement covers prototype airframes only, KTEK has confirmed it will update the market if the Vestal program leads to material follow-on orders.

Read the full contract breakdown and what it means for KTEK's customer pipeline: https://stockwirex.com/asx-stock-news/industrials/ktk-ktek-aerosystems-scooper-25-prototype-contract-september-2026/

OncoSil Medical's Australian manufacturing ambitions just cleared a critical regulatory gate.Cyclotek, OncoSil Medical's...
08/09/2026

OncoSil Medical's Australian manufacturing ambitions just cleared a critical regulatory gate.

Cyclotek, OncoSil Medical's (ASX: OSL) contract manufacturer, has received ISO 13485 certification for the company's Macquarie Park facility in Sydney โ€” confirming the site's quality management system meets international medical device manufacturing standards. The certification is a prerequisite for the next step: adding Macquarie Park as a critical subcontractor to OncoSil Medical's existing Notified Body certificate, which must be completed before commercial production can begin. The company is targeting production commencement by the end of 2Q FY27, subject to regulatory review and approval.

CEO Nigel Lange noted: "Macquarie Park is an important part of our strategy to build a scalable and capital-efficient manufacturing platform to support our growing global commercial activities. As we scale, we expect the facility to provide greater control over product quality and our supply chain, while driving manufacturing efficiencies that have the potential to significantly improve gross margins over time." The facility, designed with capital intensity of less than 5% at full capacity, is being built to serve an already-active global operation spanning 30+ countries, underpinned by TRIPP-FFX trial results showing an 82.2% local disease control rate published in June 2026.

Read the full regulatory pathway breakdown and what this milestone means for the FY27 catalyst timeline: https://stockwirex.com/asx-stock-news/biotech-health/oncosil-medical-iso-13485-certification-macquarie-park/

Biome Daily is already the number one probiotic in Australian pharmacy by units and value โ€” and until now, it only came ...
08/09/2026

Biome Daily is already the number one probiotic in Australian pharmacy by units and value โ€” and until now, it only came in a 30-pack.

Biome Australia (ASX: BIO) is launching two-month formats of its two highest-volume products in H1 FY27: Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60. The move is backed by hard market data โ€” IQVIA pharmacy scan data shows 14 of the top 20 probiotic products in Australian pharmacy by value are 60 or 90 packs, a format tier Biome has not previously competed in. Both new products use microencapsulation technology that delivers five times more live bacteria to the gut than uncoated alternatives, and will be Biome's first Australian-made products, manufactured under the recently announced Specialty Probiotics Australia agreement.

The commercial rationale goes beyond format parity. Running out is the primary reason patients discontinue probiotics, and a two-month supply directly addresses that adherence gap while lifting revenue per customer visit for pharmacy partners and reducing single-SKU supply concentration risk. The onshore manufacturing transition is also expected to lift gross margins progressively from approximately 61% to above 65% over 18 months. Founder and Managing Director Blair Vega Norfolk put it directly: "The category has already told us it wants the format. These will also be Biome's first Australian-made products."

Read the full breakdown of the product launches, format strategy, and margin outlook: https://stockwirex.com/asx-stock-news/consumer-staples/bio-biome-australia-probiotic-60-launch-september-2026/

Osteopore has secured full orthopaedic market access in Thailand, opening the door to a segment the company estimates at...
08/09/2026

Osteopore has secured full orthopaedic market access in Thailand, opening the door to a segment the company estimates at USD 60โ€“80 million annually.

Thailand's orthopaedic devices market is valued at approximately USD 749 million in 2025 and is projected to reach USD 1.5 billion by 2033, representing a 9.2% CAGR โ€” one of the fastest growth trajectories in the Asia-Pacific region. Osteopore's 3D-printed bioresorbable scaffolds sit within the bone-repair orthobiologics segment, which typically accounts for 8โ€“10% of total orthopaedic device market value. Underpinning the market entry is a distribution partnership with DCH Auriga, a regional healthcare specialist operating across Asia for over 50 years, distributing more than 500 brands across over 10,000 points of sale.

CEO Dr Yujing Lim noted: "Our team has evaluated the potential of regional markets and Thailand has been identified as one of our key markets in ASEAN. I am glad to see that the team is smoothly executing on our regional expansion plans." With Auriga acting as market authorisation holder and importer, the immediate next step is product listing in target public and private hospitals in Bangkok โ€” mirroring the pathway that followed Osteopore's earlier neurosurgery approval at Thammasat University Hospital.

Read the full breakdown of the Thailand market opportunity and what comes next for Osteopore's ASEAN expansion: https://stockwirex.com/asx-stock-news/biotech-health/osx-osteopore-thailand-orthopaedic-market-access-september-2026/

Address

202/37 Barrack Street
Perth, WA
6000

Website

Alerts

Be the first to know and let us send you an email when StockWire X posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category